NEW YORK--(BUSINESS WIRE)--Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Akorn, Inc. (“Akorn” or the “Company”) (NASDAQ:AKRX).
On February 26, 2018, Fresenius SE & Co. KGaA (“Fresenius”), the company that previously agreed to acquire Akorn, announced that it “is conducting an independent investigation, using external experts, into alleged breaches of [U.S. Food and Drug Administration] data integrity requirements relating to product development at Akorn[.]” Fresenius further stated that it “will assess the findings of th[e] investigation” and that “[t]he consummation of the transaction may be affected if the closing conditions under the merger agreement are not met.”
On this news, Akorn’s share price significantly declined, causing harm to investors.
If you invested in Akorn stock or options and would like to discuss your legal rights, click here: www.faruqilaw.com/AKRX. There is no cost or obligation to you.
You can also contact us by calling Richard Gonnello toll free at 877-247-4292 or at 212-983-9330 or by sending an e-mail to firstname.lastname@example.org.
Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.